Agios Net Interest Income from 2010 to 2026
| 8AP Stock | EUR 25.00 0.60 2.34% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 13.4 M | Current Value 12.4 M | Quarterly Volatility 6.4 M |
Check Agios Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Agios Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 116.6 M or Total Revenue of 65.8 M, as well as many indicators such as . Agios financial statements analysis is a perfect complement when working with Agios Pharmaceuticals Valuation or Volatility modules.
Agios | Net Interest Income |
The Net Interest Income trend for Agios Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Agios Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Agios Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Agios Pharmaceuticals over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Agios Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Agios Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Agios Net Interest Income Regression Statistics
| Arithmetic Mean | 14,967,409 | |
| Coefficient Of Variation | 141.35 | |
| Mean Deviation | 16,307,989 | |
| Median | 2,514,000 | |
| Standard Deviation | 21,156,987 | |
| Sample Variance | 447.6T | |
| Range | 70.4M | |
| R-Value | 0.75 | |
| Mean Square Error | 211.7T | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | 3,126,077 | |
| Total Sum of Squares | 7161.9T |
Agios Net Interest Income History
About Agios Pharmaceuticals Financial Statements
Agios Pharmaceuticals stakeholders use historical fundamental indicators, such as Agios Pharmaceuticals' Net Interest Income, to determine how well the company is positioned to perform in the future. Although Agios Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Agios Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Agios Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Agios Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 56.4 M | 59.2 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.